Andijonning COVID-19 bilan o‘troq va kelgindi populyatsiyasida o‘pka shikastlanishi tarqalishining xususiyatlari
Litsenziya: cc-by
Annotatsiya
The implementation of the results of the first study, based on epidemiological monitoring, pharmacoepidemiological analysis, and the developed preventive program, led to the following: 1) a “regional portrait” of the population with COVID-19-associated lung injury was formed, which made it possible to use it for active preventive measures, and it was widely applied in practice; 2) early diagnosis of the premorbid and comorbid background of COVID-19 lung injury was significantly improved; 3) the risk of thromboembolic complications associated with COVID-19 lung injury was reduced by more than 30% (in every third patient); 4) the number of prescribed drugs with potential risks was reduced by 30%; 5) adverse effects and manifestations of drugs in COVID-19 lung injury were prevented by up to 10%; 6) the patient mortality rate decreased by 20%, and the rate of appropriate and safe prescribing of antibiotic therapy improved by 90%. Up to 90% of patients with COVID-19-associated lung injury can be identified on the basis of timely and properly conducted preventive studies. The validity of the results is confirmed by the correct “targeted” use of epidemiological and objective criteria for assessing the condition of the patient population, as well as by modern methods of biochemical, laboratory, and instrumental diagnostics and methodological approaches. Statistical processing and analysis confirmed the reliability of the recorded epidemiological and clinical results.